Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma

• Published in: Multidisciplinary respiratory medicine Vol. 12; no. 1; pp. 16 - 8
• Main Authors: Davidsson, Elsa, Murgia, Nicola, Ortiz-Villalón, Cristian, Wiklundh, Emil, Sköld, Magnus, Kölbeck, Karl Gustav, Ferrara, Giovanni
• Format: Journal Article
• Language: English
• Published: Italy BioMed Central Ltd 03.07.2017; PAGEPress Publications; BioMed Central; Mattioli 1885
• Subjects: Adenocarcinoma; Age; Cancer therapies; Chemotherapy; Clinical medicine; Complications and side effects; Disease; Endothelial growth factors; Gender; Health risk assessment; Hospitals; Lung cancer; Medicin och hälsovetenskap; Mutation; Non-small cell lung cancer; Original; Precision medicine; Quality control; Risk factors; Thromboembolism; Thrombosis; Tyrosine kinase inhibitors; Variables; Sweden; Mutation; Precision medicine; Thromboembolism; Tyrosine kinase inhibitors; Non-small cell lung cancer

Precision medicine promises to improve prognosis of patients affected by untreatable diseases. Patients with lung cancer (especially lung adenocarcinoma) bear an increased risk of VTE. Mutations in the EGFR and rearrangement in the ALK genes identify specific subgroups of patients. Aim of this study...